FDA expands use of Simponi to include ulcerative colitis

05/15/2013 | Drug Store News

Johnson & Johnson obtained FDA approval to market Simponi, or golimumab, as a treatment for moderate to severe forms of ulcerative colitis in adults. The drug, a tumor necrosis factor inhibitor previously approved for rheumatoid arthritis, is manufactured by J&J unit Janssen Biotech.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT